suPAR in clinical routine at Hospital General Universitario Santa Lucía

Fri Jun 26 2020

By: Julio Ajenjo García, ViroGates

Hospital General Universitario Santa Lucía, situated in Cartagena, Murcia Region, on the Spanish Mediterranean coast, is a 667-bed facility. It serves around 300,000 people as a reference hospital. On June 23, the hospital began offering suPAR testing in its services. They will use this biomarker to categorize the risk of patients in the Emergency Department with acute conditions, including those under suspicion for COVID-19.

The hospital measures suPAR using the cobas c501 system from Roche Diagnostics. Dra. María Dolores Albaladejo Otón, the Head of the Clinical Analysis Service, and Dr. Luis García de Guadiana Romualdo, a Clinical Analysis Area specialist, led the technical and clinical introduction of suPAR at the hospital.

Hospital General Universitario Santa Lucía is the second hospital in Spain to incorporate suPAR into its clinical routine in the past three months.

“We are very happy to have this new biomarker that has proven to be a useful tool in the ED for making decisions about the need for hospital admission or discharge. We hope that the first results demonstrating its usefulness in patients with
COVID-19 can be confirmed soon in our hospital.”

Dra. María Dolores Albaladejo Otón,
Head of the Clinical Analysis, Hospital General Universitario Santa Lucía, Spain
suPAR News Vol. 3, June 2020


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

suPARnostic POC+

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research


Point-of-care finger prick

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates